Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(3S)-1-(3,4-dihydroxyphenyl)-7-phenyl-(6E)-6-hepten-3-ol
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
C-092 (also known as ASPP 092) is a diarylheptanoid compound isolated from the ethanol extract of *Curcuma comosa*, a medicinal plant native to Thailand. It is being investigated for its neuroprotective and antioxidant properties, particularly in the context of neurodegenerative diseases like Parkinson's disease. C-092 acts as a potent radical scavenger and an inducer of the Nrf-2 (Nuclear factor erythroid 2-related factor 2) signaling pathway, which upregulates antioxidant enzymes and maintains catalase activity. Additionally, it exhibits anti-apoptotic effects by suppressing the expression of phospho-p53 and cleaved caspase-3 in neuronal cell models.
02
Targets
NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)
Beyond the preview
Go deeper on (3S)-1-(3,4-dihydroxyphenyl)-7-phenyl-(6E)-6-hepten-3-ol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on (3S)-1-(3,4-dihydroxyphenyl)-7-phenyl-(6E)-6-hepten-3-ol.